Stryker Corporation $SYK Shares Sold by BNP Paribas

BNP Paribas lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 8.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,771 shares of the medical technology company’s stock after selling 1,911 shares during the quarter. BNP Paribas’ holdings in Stryker were worth $7,309,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Boothbay Fund Management LLC acquired a new stake in Stryker in the 3rd quarter valued at approximately $567,000. Aquatic Capital Management LLC purchased a new stake in Stryker in the third quarter valued at approximately $5,758,000. 1858 Wealth Management LLC lifted its stake in Stryker by 7.6% during the third quarter. 1858 Wealth Management LLC now owns 622 shares of the medical technology company’s stock worth $230,000 after purchasing an additional 44 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares in the last quarter. Finally, Creative Planning boosted its position in shares of Stryker by 3.2% during the third quarter. Creative Planning now owns 89,888 shares of the medical technology company’s stock worth $33,229,000 after buying an additional 2,786 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the transaction, the director directly owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 5.90% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Citi and some analysts view the pullback as a potential buying opportunity given Stryker’s fundamentals and upcoming catalysts — Citi put together a “90‑day catalyst watch” that sees upside despite the outage. Citi Sees Upside
• Positive Sentiment: Technicals may offer support: commentators note shares became oversold after the sell‑off and found support at a prior level, suggesting a possible technical bounce for traders. Stock Of The Day: Where Is The Bottom For Stryker?
• Neutral Sentiment: Stryker has publicly confirmed a cybersecurity incident and is investigating; the company is communicating updates as the situation evolves. Company Announcement
• Neutral Sentiment: Reporting shows the attack is causing real operational disruption to order processing, manufacturing and shipments — facts investors must watch to judge duration and revenue impact. Reuters: Disruption Report
• Negative Sentiment: Hackers claiming Iran linkage (group “Handala”) say the attack included destructive “wiper” activity and exfiltration of large volumes of data — allegations that raise the risk of extended downtime and regulatory/PR fallout. IBTimes: Hacker Claim
• Negative Sentiment: Operational paralysis from the incident has already pressured the stock, with multiple outlets reporting multi‑percent intraday declines as orders and shipments stall. Yahoo: Shares Fall
• Negative Sentiment: Social‑media driven selling amplified volatility — a viral Reddit thread and related headlines accelerated the recent drop, adding short‑term downside risk beyond fundamentals. 24/7 Wall St.: Reddit Impact

Stryker Stock Down 0.1%

Stryker stock opened at $336.95 on Friday. The firm has a market capitalization of $128.95 billion, a P/E ratio of 40.11, a P/E/G ratio of 1.97 and a beta of 0.85. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. Stryker Corporation has a twelve month low of $328.23 and a twelve month high of $404.87. The stock’s fifty day simple moving average is $365.20 and its 200-day simple moving average is $367.52.

Stryker (NYSE:SYK) last released its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same period last year, the business posted $4.01 earnings per share. Stryker’s revenue was up 11.4% compared to the same quarter last year. As a group, equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on SYK shares. UBS Group boosted their price objective on Stryker from $386.00 to $400.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. The Goldman Sachs Group set a $399.00 target price on Stryker in a report on Friday, January 9th. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. William Blair reiterated an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Finally, Citizens Jmp raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price target on the stock in a research report on Friday, December 19th. Fourteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $428.61.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.